Therapyradionuclidepeptide receptor an emerging treatment for gastrointestinal neuroendocrine tumors

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Neuroendocrine tumors (NETs) are comprised of biologically diverse neoplasms. The presence of systemic symptoms is dependent on NET location and differentiation. New treatment modalities have become available, offering patients improved symptom management and survival. Advanced practice RNs (APRNs) provide direct care to and coordination of treatment for patients with NETs, including treatment of somatostatin receptor–positive disease with lutetium Lu 177 dotatate (Lutathera®) peptide receptor radionuclide therapy. AT A GLANCEɔ NETs are complex and may cause a variety of symptoms, such as those associated with carcinoid syndrome.ɔ APRNs are key members of the interprofessional team and are involved in the diagnosis, treat-ment, and coordination of care of patients with NETs.ɔ Somatostatin receptor–positive NETs may be treated with targeted treatments containing radioactive isotopes, such as lutetium Lu 177 dotatate.

Original languageEnglish
Pages (from-to)129-133
Number of pages5
JournalClinical Journal of Oncology Nursing
Issue number2
StatePublished - Apr 2020

Bibliographical note

Publisher Copyright:
© 2020, Oncology Nursing Society. All rights reserved.


  • Carcinoid syndrome
  • Neuroendo-crine
  • Peptide receptor radionuclide therapy (PRRT)

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)


Dive into the research topics of 'Therapyradionuclidepeptide receptor an emerging treatment for gastrointestinal neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this